Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 10, 2012

View Archived Issues

Shionogi reports on first quarter of 2012

Synthetic Biologics to use Intrexon technology for mAb development

Genkyotex product attenuates liver fibrosis in vivo

University of Queensland researcher receives grant for nanoparticle delivery system

Novel computational method pairs known drugs with new uses

Researchers describe vaccine's cross-reactivity against Nipah virus

Abbott designs novel ALK blockers

Research at Actelion yields new S1P1 receptor agonists

Actinium and Philogen partner to develop adhesion-targeted anticancer radiotherapies

Dutch regulatory agency denies approval of Cortiment

New HDAC8/HDAC6 inhibitors patented

Salix and Alfa Wassermann enter agreement for EIR rifaximin formulation

FDA requests new validated test system for immunoglobulin preparation

McGill University presents new antibiotics

Topically delivered nanoparticle-siRNA conjugates suppress gene expression in vivo

Astellas and AstraZeneca gain approval in Japan for COPD therapeutic

Novel beta-secretase inhibitors created at Eisai

Japanese MHLW approves Bactramin/Baktar for additional indication

Humira approved for additional indication in Japan

Acquisition of Amylin Pharmaceuticals complete

AnaMar to conduct phase II studies of new analgesic and anti-inflammatory drug

Clovis Oncology launches CP-4126 combination trial

Galenea and CHDI Foundation extend and expand Huntington's disease collaboration

Nodality and Pfizer enter multiyear strategic collaboration

Sunitinib capsules approved in Japan for treatment of pancreatic neuroendocrine tumors

Japanese authorities grant new approval to ultrasound contrast agent

Flagyl approved for additional indication in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...